1 2 3 4 5 British national formulary : BNF 76 (76 ed.)
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, but concerns about tirzepatide and thyroid nodules have emerged from animal studies showing thyroid C-cell tumors in rodents
The study population included 85,223 patients with obesity who were prescribed semaglutide or non-GLP-1RA anti-obesity medications, with the findings replicated in 596,045 patients with T2D
With an increase in the incidence of noncommunicable diseases (NCDs) such as diabetes, cardiomyopathies, cancers, and epilepsy, which are often associated with oxidative stress, people resort to the use of dietary supplements (known antioxidants) to prevent these diseases [2]
Retatrutide works through incretin and glucagon pathways
[DOI] [PMC free article] [PubMed] [Google Scholar] 95.Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ